Rapidly increasing use of proton pump inhibitors prescribed in primary care: a nationwide observational study

Publikation: Konferencebidrag uden forlag/tidsskriftPosterForskningpeer review

Resumé

Background: Antisecretory drugs (ADs) are often prescribed in primary care for upper gastrointestinal symptoms. Reimbursement modifications have been made in Denmark to minimize costs related to use of ADs. However knowledge about development in use of ADs over the past decade and the impacts of the reimbursement modifications is sparse.

Research questions: How has use of ADs developed in Denmark 2001-2011? Which impacts have the reimbursement modifications had on the use of ADs?

Methods: The Register of Medicinal Product Statistics includes all sales and redeemed prescriptions nationwide covering the entire Danish population of currently 5.5 million inhabitants. The register was searched September 2012 for the ADs proton-pump inhibitors (PPIs) and histamine-2-receptor antagonists. The variables turnover, paid reimbursement, volume sold, sector (primary vs. hospital), age, gender and number of users through the years 2001-2011 were used. Data from prescriptions redeemed by persons younger than 20 years were excluded. Prescriptions for ulcerogenic drugs (acetylsalicylic acid and non-steroidal anti-inflammatory drugs) redeemed by persons aged 65 years and older were included since ulcer prophylaxis could be an indication for prescribing ADs to that age group.

Results: PPIs are the far most commonly prescribed AD and 96.5 % are prescribed in primary care. Use of PPIs has increased by 243 % through the past decade. Both number of users and the average individual use has increased. There has not been a change in indications for use of PPIs in the same time range. Use of ulcerogenic drugs among the elderly has stagnated. Reimbursement modifications do not seem to have had a substantial influence on the steadily increasing use of PPIs.

Conclusions: Use of PPIs has increased substantially the past decade. Reimbursement modifications do not seem to have had a substantial influence on the steadily increasing use.
OriginalsprogEngelsk
Publikationsdatomaj 2013
StatusUdgivet - maj 2013
BegivenhedEuropean General Practice Research Network - Kusadasi, Tyrkiet
Varighed: 16. maj 201319. maj 2013

Konference

KonferenceEuropean General Practice Research Network
LandTyrkiet
ByKusadasi
Periode16/05/201319/05/2013

Citer dette

Haastrup, P., Jarbøl, D. E., & Hansen, J. M. (2013). Rapidly increasing use of proton pump inhibitors prescribed in primary care: a nationwide observational study. Poster session præsenteret på European General Practice Research Network, Kusadasi, Tyrkiet.
@conference{eafd705f15af468fb9b03d62f8f10fd3,
title = "Rapidly increasing use of proton pump inhibitors prescribed in primary care: a nationwide observational study",
abstract = "Background: Antisecretory drugs (ADs) are often prescribed in primary care for upper gastrointestinal symptoms. Reimbursement modifications have been made in Denmark to minimize costs related to use of ADs. However knowledge about development in use of ADs over the past decade and the impacts of the reimbursement modifications is sparse.Research questions: How has use of ADs developed in Denmark 2001-2011? Which impacts have the reimbursement modifications had on the use of ADs?Methods: The Register of Medicinal Product Statistics includes all sales and redeemed prescriptions nationwide covering the entire Danish population of currently 5.5 million inhabitants. The register was searched September 2012 for the ADs proton-pump inhibitors (PPIs) and histamine-2-receptor antagonists. The variables turnover, paid reimbursement, volume sold, sector (primary vs. hospital), age, gender and number of users through the years 2001-2011 were used. Data from prescriptions redeemed by persons younger than 20 years were excluded. Prescriptions for ulcerogenic drugs (acetylsalicylic acid and non-steroidal anti-inflammatory drugs) redeemed by persons aged 65 years and older were included since ulcer prophylaxis could be an indication for prescribing ADs to that age group. Results: PPIs are the far most commonly prescribed AD and 96.5 {\%} are prescribed in primary care. Use of PPIs has increased by 243 {\%} through the past decade. Both number of users and the average individual use has increased. There has not been a change in indications for use of PPIs in the same time range. Use of ulcerogenic drugs among the elderly has stagnated. Reimbursement modifications do not seem to have had a substantial influence on the steadily increasing use of PPIs.Conclusions: Use of PPIs has increased substantially the past decade. Reimbursement modifications do not seem to have had a substantial influence on the steadily increasing use.",
author = "Peter Haastrup and Jarb{\o}l, {Dorte Ejg} and Hansen, {Jane M{\o}ller}",
year = "2013",
month = "5",
language = "English",
note = "null ; Conference date: 16-05-2013 Through 19-05-2013",

}

Haastrup, P, Jarbøl, DE & Hansen, JM 2013, 'Rapidly increasing use of proton pump inhibitors prescribed in primary care: a nationwide observational study' European General Practice Research Network, Kusadasi, Tyrkiet, 16/05/2013 - 19/05/2013, .

Rapidly increasing use of proton pump inhibitors prescribed in primary care: a nationwide observational study. / Haastrup, Peter ; Jarbøl, Dorte Ejg; Hansen, Jane Møller.

2013. Poster session præsenteret på European General Practice Research Network, Kusadasi, Tyrkiet.

Publikation: Konferencebidrag uden forlag/tidsskriftPosterForskningpeer review

TY - CONF

T1 - Rapidly increasing use of proton pump inhibitors prescribed in primary care: a nationwide observational study

AU - Haastrup, Peter

AU - Jarbøl, Dorte Ejg

AU - Hansen, Jane Møller

PY - 2013/5

Y1 - 2013/5

N2 - Background: Antisecretory drugs (ADs) are often prescribed in primary care for upper gastrointestinal symptoms. Reimbursement modifications have been made in Denmark to minimize costs related to use of ADs. However knowledge about development in use of ADs over the past decade and the impacts of the reimbursement modifications is sparse.Research questions: How has use of ADs developed in Denmark 2001-2011? Which impacts have the reimbursement modifications had on the use of ADs?Methods: The Register of Medicinal Product Statistics includes all sales and redeemed prescriptions nationwide covering the entire Danish population of currently 5.5 million inhabitants. The register was searched September 2012 for the ADs proton-pump inhibitors (PPIs) and histamine-2-receptor antagonists. The variables turnover, paid reimbursement, volume sold, sector (primary vs. hospital), age, gender and number of users through the years 2001-2011 were used. Data from prescriptions redeemed by persons younger than 20 years were excluded. Prescriptions for ulcerogenic drugs (acetylsalicylic acid and non-steroidal anti-inflammatory drugs) redeemed by persons aged 65 years and older were included since ulcer prophylaxis could be an indication for prescribing ADs to that age group. Results: PPIs are the far most commonly prescribed AD and 96.5 % are prescribed in primary care. Use of PPIs has increased by 243 % through the past decade. Both number of users and the average individual use has increased. There has not been a change in indications for use of PPIs in the same time range. Use of ulcerogenic drugs among the elderly has stagnated. Reimbursement modifications do not seem to have had a substantial influence on the steadily increasing use of PPIs.Conclusions: Use of PPIs has increased substantially the past decade. Reimbursement modifications do not seem to have had a substantial influence on the steadily increasing use.

AB - Background: Antisecretory drugs (ADs) are often prescribed in primary care for upper gastrointestinal symptoms. Reimbursement modifications have been made in Denmark to minimize costs related to use of ADs. However knowledge about development in use of ADs over the past decade and the impacts of the reimbursement modifications is sparse.Research questions: How has use of ADs developed in Denmark 2001-2011? Which impacts have the reimbursement modifications had on the use of ADs?Methods: The Register of Medicinal Product Statistics includes all sales and redeemed prescriptions nationwide covering the entire Danish population of currently 5.5 million inhabitants. The register was searched September 2012 for the ADs proton-pump inhibitors (PPIs) and histamine-2-receptor antagonists. The variables turnover, paid reimbursement, volume sold, sector (primary vs. hospital), age, gender and number of users through the years 2001-2011 were used. Data from prescriptions redeemed by persons younger than 20 years were excluded. Prescriptions for ulcerogenic drugs (acetylsalicylic acid and non-steroidal anti-inflammatory drugs) redeemed by persons aged 65 years and older were included since ulcer prophylaxis could be an indication for prescribing ADs to that age group. Results: PPIs are the far most commonly prescribed AD and 96.5 % are prescribed in primary care. Use of PPIs has increased by 243 % through the past decade. Both number of users and the average individual use has increased. There has not been a change in indications for use of PPIs in the same time range. Use of ulcerogenic drugs among the elderly has stagnated. Reimbursement modifications do not seem to have had a substantial influence on the steadily increasing use of PPIs.Conclusions: Use of PPIs has increased substantially the past decade. Reimbursement modifications do not seem to have had a substantial influence on the steadily increasing use.

M3 - Poster

ER -

Haastrup P, Jarbøl DE, Hansen JM. Rapidly increasing use of proton pump inhibitors prescribed in primary care: a nationwide observational study. 2013. Poster session præsenteret på European General Practice Research Network, Kusadasi, Tyrkiet.